Ipilimumab in real-world clinical practice

efficacy and safety data from a multicenter observational study

Alberto Russi, Vera Damuzzo, Marco Chiumente, Jacopo Pigozzo, Marco Cesca, Vanna Chiarion-Sileni, Angelo Claudio Palozzo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In patients with metastatic melanoma, ipilimumab has been shown to improve long-term survival. This observational multicenter study reports clinical outcomes of 418 patients treated with second-line ipilimumab from February 2013 to August 2014. Median overall survival (OS) was 6.43 months (95%CI: 5.45-7.42; n = 300), while median progression-free survival (PFS) was 3.7 months (95%CI: 3.23-4.17; n = 188). Demographic factors, such as sex or number of previous therapies did not affect OS. Survival was shorter in patients with ECOG > 0 (Eastern Cooperative Oncology Group, Performance Status) (p < 0.001), while a longer OS was found in patients who completed all four therapy cycles (p < 0.001). Adverse events of any grade were reported for 66% of patients (mainly cutaneous and gastrointestinal), but most were low grade and easily managed. Adverse events of grades 3-4 were observed in 13% of patients. This study confirmed the efficacy and safety of this treatment in real practice.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalJournal of Chemotherapy
Volume29
Issue number4
DOIs
Publication statusPublished - Aug 2017

Fingerprint

Multicenter Studies
Observational Studies
Safety
Survival
Disease-Free Survival
ipilimumab
Melanoma
Demography
Skin
Therapeutics

Keywords

  • Journal Article

Cite this

Ipilimumab in real-world clinical practice : efficacy and safety data from a multicenter observational study. / Russi, Alberto; Damuzzo, Vera; Chiumente, Marco; Pigozzo, Jacopo; Cesca, Marco; Chiarion-Sileni, Vanna; Palozzo, Angelo Claudio.

In: Journal of Chemotherapy, Vol. 29, No. 4, 08.2017, p. 245-251.

Research output: Contribution to journalArticle

Russi, Alberto ; Damuzzo, Vera ; Chiumente, Marco ; Pigozzo, Jacopo ; Cesca, Marco ; Chiarion-Sileni, Vanna ; Palozzo, Angelo Claudio. / Ipilimumab in real-world clinical practice : efficacy and safety data from a multicenter observational study. In: Journal of Chemotherapy. 2017 ; Vol. 29, No. 4. pp. 245-251.
@article{e750119730d44602aac4b5546e566c70,
title = "Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study",
abstract = "In patients with metastatic melanoma, ipilimumab has been shown to improve long-term survival. This observational multicenter study reports clinical outcomes of 418 patients treated with second-line ipilimumab from February 2013 to August 2014. Median overall survival (OS) was 6.43 months (95{\%}CI: 5.45-7.42; n = 300), while median progression-free survival (PFS) was 3.7 months (95{\%}CI: 3.23-4.17; n = 188). Demographic factors, such as sex or number of previous therapies did not affect OS. Survival was shorter in patients with ECOG > 0 (Eastern Cooperative Oncology Group, Performance Status) (p < 0.001), while a longer OS was found in patients who completed all four therapy cycles (p < 0.001). Adverse events of any grade were reported for 66{\%} of patients (mainly cutaneous and gastrointestinal), but most were low grade and easily managed. Adverse events of grades 3-4 were observed in 13{\%} of patients. This study confirmed the efficacy and safety of this treatment in real practice.",
keywords = "Journal Article",
author = "Alberto Russi and Vera Damuzzo and Marco Chiumente and Jacopo Pigozzo and Marco Cesca and Vanna Chiarion-Sileni and Palozzo, {Angelo Claudio}",
year = "2017",
month = "8",
doi = "10.1080/1120009X.2017.1311444",
language = "English",
volume = "29",
pages = "245--251",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Ipilimumab in real-world clinical practice

T2 - efficacy and safety data from a multicenter observational study

AU - Russi, Alberto

AU - Damuzzo, Vera

AU - Chiumente, Marco

AU - Pigozzo, Jacopo

AU - Cesca, Marco

AU - Chiarion-Sileni, Vanna

AU - Palozzo, Angelo Claudio

PY - 2017/8

Y1 - 2017/8

N2 - In patients with metastatic melanoma, ipilimumab has been shown to improve long-term survival. This observational multicenter study reports clinical outcomes of 418 patients treated with second-line ipilimumab from February 2013 to August 2014. Median overall survival (OS) was 6.43 months (95%CI: 5.45-7.42; n = 300), while median progression-free survival (PFS) was 3.7 months (95%CI: 3.23-4.17; n = 188). Demographic factors, such as sex or number of previous therapies did not affect OS. Survival was shorter in patients with ECOG > 0 (Eastern Cooperative Oncology Group, Performance Status) (p < 0.001), while a longer OS was found in patients who completed all four therapy cycles (p < 0.001). Adverse events of any grade were reported for 66% of patients (mainly cutaneous and gastrointestinal), but most were low grade and easily managed. Adverse events of grades 3-4 were observed in 13% of patients. This study confirmed the efficacy and safety of this treatment in real practice.

AB - In patients with metastatic melanoma, ipilimumab has been shown to improve long-term survival. This observational multicenter study reports clinical outcomes of 418 patients treated with second-line ipilimumab from February 2013 to August 2014. Median overall survival (OS) was 6.43 months (95%CI: 5.45-7.42; n = 300), while median progression-free survival (PFS) was 3.7 months (95%CI: 3.23-4.17; n = 188). Demographic factors, such as sex or number of previous therapies did not affect OS. Survival was shorter in patients with ECOG > 0 (Eastern Cooperative Oncology Group, Performance Status) (p < 0.001), while a longer OS was found in patients who completed all four therapy cycles (p < 0.001). Adverse events of any grade were reported for 66% of patients (mainly cutaneous and gastrointestinal), but most were low grade and easily managed. Adverse events of grades 3-4 were observed in 13% of patients. This study confirmed the efficacy and safety of this treatment in real practice.

KW - Journal Article

U2 - 10.1080/1120009X.2017.1311444

DO - 10.1080/1120009X.2017.1311444

M3 - Article

VL - 29

SP - 245

EP - 251

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -